Clinical trials - page 6

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphom.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced-Stage Follicular Lymphoma (GOLSEEK-2)"

Phase Ib Dose Finding Study Assessing Safety and Activity;of [;177Lu]LuNeob in combination with ribocilcib and fulvestrant;in subjects with HR positive, HER2 negative breast cancer,;experiencing early relapse from (neo)adjuvant endocrine;therapy.

A prospective, multicenter, open-label, randomized international Phase III study evaluating treatment with lutetium (177Lu) vipivotide tetraxetan (AAA617) versus surveillance alone to delay the need for castration or disease recurrence in adult male patients with PSMA-positive oligometastatic prostate cancer.

CAMBRIA-2: A Phase III, Randomised, Open-label Study to Evaluate the Efficacy and Safety of Camizestrant (AZD9833), a Next Generation Oral Selective Estrogen Receptor Degrader (ngSERD), Compared with Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment in Patients with Estrogen Receptor-positive, HER2-negative Early Breast Cancer at Medium to High or High Risk of Recurrence, Who Have Completed Definitive Locoregional Therapy and Have No Evidence of Disease.

A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer

A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer.

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA).

An open label, multi-center roll-over study to assess longterm;effect in pediatric patients treated with Tafinlar;(dabrafenib) and/or Mekinist (trametinib)